TY - JOUR

T1 - Symptoms of anxiety and depression are frequent in patients with acute hepatitis C and are not associated with disease severity

AU - Deterding, Katja

AU - Grüner, Norbert

AU - Buggisch, Peter

AU - Galle, Peter R.

AU - Spengler, Ulrich

AU - Hinrichsen, Holger

AU - Berg, Thomas

AU - Potthoff, Andrej

AU - Großhennig, Anika

AU - Koch, Armin

AU - Diepolder, Helmut

AU - Lüth, Stefan

AU - Feyerabend, Sandra

AU - Jung, Maria C.

AU - Rogalska-Taranta, Magdalena

AU - Schlaphoff, Verena

AU - Cornberg, Markus

AU - Manns, Michael P.

AU - Wedemeyer, Heiner

AU - Wiegand, Johannes

AU - Hep-Net Acute HCV-III Study Group

N1 - Funding Information: The Hep-Net Acute HCV-III study was supported by the German Network of Competence on Viral Hepatitis (Hep- Net, funded by the Federal Ministry of Education and Research). The Hep-Net study house supported central study facilities, data acquisition, randomization, study management, and data monitoring. The study was also supported by a research grant from Essex Pharma/Schering-Plough/MSD. MSD provided medication and financial support. K.D. received lecture fees from MSD, AbbVie, Gilead, BMS and travel support from MSD and Gilead. P.B. received speaker’s honoraria and consultant fees. T.B. is on the advisory board and received grants, lecture and consultant fees and travel support from Roche, Gilead, Janssen, Merck, AbbVie and BMS. S.L. is on the advisory board and received grants, lecture and consultant fees and travel support. M.C. is on the advisory board of Merck, Gilead, BMS, AbbVie and on the Board membership of Roche and Novartis; he received grants and consultant and lecture fees from Merck, Roche, Gilead, BMS, AbbVie, Novartis and payment for development of educational presentations from Merck. M.P.M. has received honoraria for consulting and speaking from Achillion, BMS, Gilead, GlaxoSmithKline, Janssen-Cilag, Medgenics, Merck/ Schering-Plough, Novartis, Roche and Vertex and research grants from AbbVie, BMS, Gilead, Merck, Novartis, Roche, Roche Diagnostics and Siemens. H.W. has received honoraria for consulting or speaking and grants from AbbVie, Abbott, BMS, Gilead, Merck/Schering-Plough, Novartis, Roche, Roche Diagnostics, Siemens Biolex, Boehringer Ingelheim, Eiger Pharmaceuticals, Falk Foundation, Janssen-Cilag, Medgenics, Novira and Transgene. For the remaining authors there are no conflicts of interest. Publisher Copyright: © 2016 Wolters Kluwer Health, Inc. All rights reserved.

PY - 2016

Y1 - 2016

N2 - Objective Neuropsychiatric symptoms of hepatitis C virus (HCV) infection and during peginterferon á therapy have been investigated in the chronic stage of the infection, but have not been described during the acute phase of the disease so far. We therefore evaluated anxiety and depression in patients with acute hepatitis C by the Hospital Anxiety and Depression Scale (HADS) within a clinical trial. Methods Data were analysed from the German Hep-Net Acute HCV-III study. Anxiety and depression were characterized by an anxiety (HADS-A) and a depression subscale (HADS-D). More than eight points in each subscale were considered clinically relevant. Data were prospectively collected at baseline, end of treatment and at the end of the study. Results At baseline, a HADS-A above eight points was observed significantly more frequently than a HADS-D above eight points [n =23/103 (22%) vs. n= 12/103 (12%); P= 0.041]. A pathological HADS-A or HADS-D score did not correlate with age, sex, IL28B genotype, the probable mode of infection, HCV genotype or severity of disease as investigated by alanine aminotransferase and bilirubin levels. Antiviral therapy did not influence anxiety as 12/50 (24%) of patients had HADS-A above 8 at the end of therapy. The proportion of patients with HADS-D above eight points increased from 12% at baseline to 24% (n =12/50) at the end of therapy (P= 0.06). HADS results were not associated with lost to follow-up or sustained virological response rates. Conclusion HADS data in acute HCV infection indicate that anxiety and depression do not correlate with severity of the disease, mode of acquisition, lost to follow-up and sustained virological response rates.

AB - Objective Neuropsychiatric symptoms of hepatitis C virus (HCV) infection and during peginterferon á therapy have been investigated in the chronic stage of the infection, but have not been described during the acute phase of the disease so far. We therefore evaluated anxiety and depression in patients with acute hepatitis C by the Hospital Anxiety and Depression Scale (HADS) within a clinical trial. Methods Data were analysed from the German Hep-Net Acute HCV-III study. Anxiety and depression were characterized by an anxiety (HADS-A) and a depression subscale (HADS-D). More than eight points in each subscale were considered clinically relevant. Data were prospectively collected at baseline, end of treatment and at the end of the study. Results At baseline, a HADS-A above eight points was observed significantly more frequently than a HADS-D above eight points [n =23/103 (22%) vs. n= 12/103 (12%); P= 0.041]. A pathological HADS-A or HADS-D score did not correlate with age, sex, IL28B genotype, the probable mode of infection, HCV genotype or severity of disease as investigated by alanine aminotransferase and bilirubin levels. Antiviral therapy did not influence anxiety as 12/50 (24%) of patients had HADS-A above 8 at the end of therapy. The proportion of patients with HADS-D above eight points increased from 12% at baseline to 24% (n =12/50) at the end of therapy (P= 0.06). HADS results were not associated with lost to follow-up or sustained virological response rates. Conclusion HADS data in acute HCV infection indicate that anxiety and depression do not correlate with severity of the disease, mode of acquisition, lost to follow-up and sustained virological response rates.

KW - Acute hepatitis C

KW - Hospital Anxiety and Depression Scale

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=84952631176&partnerID=8YFLogxK

U2 - 10.1097/MEG.0000000000000517

DO - 10.1097/MEG.0000000000000517

M3 - Journal article

C2 - 26575158

AN - SCOPUS:84952631176

VL - 28

SP - 187

EP - 192

JO - European Journal of Gastroenterology and Hepatology, Supplement

JF - European Journal of Gastroenterology and Hepatology, Supplement

SN - 0954-691X

IS - 2

ER -